ES2179187T3 - Oriteuba qye se yba a cd40 para estimular una respuesta inmune. - Google Patents

Oriteuba qye se yba a cd40 para estimular una respuesta inmune.

Info

Publication number
ES2179187T3
ES2179187T3 ES96909555T ES96909555T ES2179187T3 ES 2179187 T3 ES2179187 T3 ES 2179187T3 ES 96909555 T ES96909555 T ES 96909555T ES 96909555 T ES96909555 T ES 96909555T ES 2179187 T3 ES2179187 T3 ES 2179187T3
Authority
ES
Spain
Prior art keywords
immune response
oriteuba
qye
stimulate
going
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909555T
Other languages
English (en)
Inventor
Mark Alderson
Kim A Campbell
Mary K Kennedy
Charles R Maliszewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ES2179187T3 publication Critical patent/ES2179187T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

SE DESCUBRE UN METODO PARA ESTIMULAR UNA RESPUESTA INMUNITARIA QUE COMPRENDE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UNA PROTEINA DE UNION A CD40. EL METODO ES UTIL EN EL TRATAMIENTO DE INDIVIDUOS INFECTADOS CON ORGANISMOS PATOGENOS U OPORTUNISTAS, E INDIVIDUOS CON UNA RESPUESTA INMUNITARIA CELULAR DISMINUIDA. LAS PROTEINAS DE UNION A CD40 INCLUYEN LIGANDO CD40, ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECIFICAMENTE A CD40 Y COMBINACIONES DE LOS MISMOS.
ES96909555T 1995-03-01 1996-02-29 Oriteuba qye se yba a cd40 para estimular una respuesta inmune. Expired - Lifetime ES2179187T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01

Publications (1)

Publication Number Publication Date
ES2179187T3 true ES2179187T3 (es) 2003-01-16

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909555T Expired - Lifetime ES2179187T3 (es) 1995-03-01 1996-02-29 Oriteuba qye se yba a cd40 para estimular una respuesta inmune.

Country Status (15)

Country Link
EP (1) EP0812206B1 (es)
JP (1) JP3657271B2 (es)
KR (1) KR19980702490A (es)
AT (1) ATE220331T1 (es)
AU (1) AU699291B2 (es)
CA (1) CA2213798C (es)
DE (1) DE69622259T2 (es)
DK (1) DK0812206T3 (es)
ES (1) ES2179187T3 (es)
FI (1) FI973484A (es)
MX (1) MX9706588A (es)
NO (1) NO973875L (es)
NZ (1) NZ305083A (es)
PT (1) PT812206E (es)
WO (1) WO1996026735A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033406A4 (en) * 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
WO1999032138A1 (en) * 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
DK1082141T3 (da) * 1998-05-23 2005-12-05 Univ Leiden Medical Ct CD40-bindende molekyler og CTL-peptider til behandling af tumorer
WO2001056602A2 (en) 2000-02-02 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
DK2066339T3 (da) 2006-09-18 2014-11-03 Univ Arkansas Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
AU2008318615A1 (en) 2007-10-30 2009-05-07 Texas A&M University System Compositions and methods of enhancing immune responses to flagellated bacterium
DK3097926T3 (da) 2007-11-01 2019-12-16 Univ Arkansas Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria
EA023058B1 (ru) 2010-01-21 2016-04-29 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Вакцинные векторы и способы усиления иммунных ответов
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
CN110066335B (zh) 2012-10-30 2024-04-05 埃派斯进有限公司 抗-cd40抗体及其使用方法
PT2956165T (pt) 2013-02-14 2019-11-29 Texas A & M Univ Sys Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0822199T3 (da) * 1991-10-25 2004-12-27 Amgen Inc N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
ATE255906T1 (de) * 1993-10-01 2003-12-15 Immunex Corp Antikörper gegen cd40

Also Published As

Publication number Publication date
KR19980702490A (ko) 1998-07-15
EP0812206A1 (en) 1997-12-17
NZ305083A (en) 1999-06-29
WO1996026735A1 (en) 1996-09-06
CA2213798C (en) 2001-02-06
DK0812206T3 (da) 2002-09-09
NO973875L (no) 1997-10-31
EP0812206B1 (en) 2002-07-10
ATE220331T1 (de) 2002-07-15
AU5301196A (en) 1996-09-18
NO973875D0 (no) 1997-08-22
DE69622259D1 (de) 2002-08-14
JP3657271B2 (ja) 2005-06-08
JPH11506418A (ja) 1999-06-08
DE69622259T2 (de) 2003-03-27
CA2213798A1 (en) 1996-09-06
PT812206E (pt) 2002-11-29
FI973484A0 (fi) 1997-08-25
MX9706588A (es) 1997-11-29
AU699291B2 (en) 1998-11-26
FI973484A (fi) 1997-10-24

Similar Documents

Publication Publication Date Title
ES2179187T3 (es) Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
ATE163195T1 (de) Lösliche liganden für cd40
FI963004A0 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
PT724456E (pt) Anticorpos contra cd4
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
EE9600192A (et) Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamine
EA199800946A1 (ru) Концентрированный препарат антител
NO971059L (no) Modifiserte human-C3-proteiner
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
EA200400134A1 (ru) Терапевтический агент
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
ATE309371T1 (de) Protein mit dnase-aktivität
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers